Blair William & Co. IL Decreases Position in Glaukos Co. (NYSE:GKOS)

Blair William & Co. IL lowered its position in Glaukos Co. (NYSE:GKOS) by 1.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,404 shares of the medical instruments supplier’s stock after selling 669 shares during the quarter. Blair William & Co. IL owned 0.09% of Glaukos worth $7,108,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in GKOS. IFP Advisors Inc purchased a new position in Glaukos during the 4th quarter valued at about $43,000. Asset Planning Inc purchased a new position in shares of Glaukos during the 4th quarter worth approximately $90,000. Picton Mahoney Asset Management acquired a new position in shares of Glaukos during the 4th quarter worth approximately $125,000. SBI Securities Co. Ltd. purchased a new stake in Glaukos in the 4th quarter valued at approximately $153,000. Finally, Smartleaf Asset Management LLC increased its position in Glaukos by 275.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock worth $164,000 after buying an additional 807 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Activity at Glaukos

In other news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

Glaukos stock opened at $101.97 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a 12 month low of $88.16 and a 12 month high of $163.71. The company has a market cap of $5.77 billion, a price-to-earnings ratio of -35.53 and a beta of 0.99. The stock’s 50-day moving average is $130.52 and its 200-day moving average is $135.71.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Equities analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Stifel Nicolaus increased their price objective on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. Piper Sandler reiterated an “overweight” rating and set a $180.00 price target (up from $140.00) on shares of Glaukos in a report on Monday, January 27th. Wells Fargo & Company upped their price objective on shares of Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Morgan Stanley cut shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a research note on Monday, December 2nd. Finally, Mizuho raised Glaukos from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $140.00 to $200.00 in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and an average price target of $163.25.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.